Endotoxin Inhibitor TFA is a synthetic peptide that exhibits high-affinity binding to lipid A, effectively detoxifying LPS and impeding LPS-induced cytokine release in vivo. It also suppresses the febrile response to LPS while demonstrating minimal toxicity and lethality [1].

The endotoxin inhibitor TFA, when administered intraperitoneally (i.p.) at a dose of 0.5 mg/kg, significantly reduces the heat exposure-induced increase in the mRNA levels of IL-1β, COX-2, IκB-β, and LPS activity. Additionally, it mitigates the hypothermia and plasma ACTH and catecholamine responses elicited by heat exposure in aged rats [1].